UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

12 Providing U.S. Policy Actions on Rare Disease

Read More Share:

Feb

03 Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

Read More Share:

Jan

31 Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

Read More Share:

Jan

16 UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

Read More Share:

Dec

18 Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

Read More Share:

Dec

06 UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

Read More Share:

Nov

26 UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Read More Share:

Nov

20 Closing gaps in HS care through community engagement and scientific innovation

Read More Share:

Nov

20 UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:

Nov

14 New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:

Categories

Archives

Feb

12

Providing U.S. Policy Actions on Rare Disease

Feb

03

Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

Jan

31

Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

Jan

16

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

Dec

18

Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

Dec

06

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

Nov

26

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Feb

12

Providing U.S. Policy Actions on Rare Disease

Feb

03

Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented

Jan

31

Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape

Jan

16

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

Dec

18

Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions

Dec

06

UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting

Nov

26

UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact